This Ph.D. work aimed to prepare a novel, innovative meloxicam-loaded polymeric micellar formulation for intranasal administration under a quality-driven basis which can deliver the model drug to the central nervous system more efficiently compared to currently commercialized formulations. The fulfillment of the expected advanced pharmacokinetic profile lies in the proper colloidal and particle characteristics and the increased water solubility induced drug release and permeability enhancement. Thus, the research work was conducted accordingly to the following steps:
I.Based on our previous work, to establish a knowledge space and perform an initial risk assessment specified for the named active substance, applied micelle-forming co-polymer, the excipients, the formulation method and the desired drug delivery route. This was performed under the extended Quality by Design risk assessment procedure for the early stages of research and development process in a preclinical setting.
II.To optimize the formulation strategy and composition via factorial design to achieve nano particle sized, monodisperse polymeric micelles with adequate colloidal stability based on their zeta potential value. To determine the fulfillment of the intranasal administration: osmolality and viscosity.
III.To describe and evaluate the quantities and qualities related to the increase in water solubility. Also, to investigate the physical stability of the formulation in a long-term study accordingly to the International Council for Harmonization (ICH) Q1A guideline and to determine its physicochemical background.
IV.To describe the nasal applicability of the formulation based on the route of the carrier system. At first, in vitro drug release study was performed, followed by in vitro mucoadhesion study at nasal conditions. Followed by in vitro cytotoxicity and permeability studies on human RPMI 2650 nasal epithelial cell line, we aimed to describe the cellular effects and transport across the nasal mucosa. Ex vivo human, nasal mucosal permeability study was also performed. The polymeric micellar system meets the requirements if increased permeability values are achieved.
V.Lastly, we aimed to investigate the in vivo pharmacokinetic behavior of the formulation after nasal administration and to calculate and describe the related kinetic profile. To evaluate at this preclinical state the aimed burst-like and rapid drug transport to the central nervous system and whether our in vitro and ex vivo studies are validated.